白消安是造血干细胞移植(HSCT)前大剂量预处理方案中的常用药物,患者间存在较大的药代动力学差异和较高的不良反应发生率。白消安主要通过谷胱甘肽转移酶(GST)催化,在肝脏与谷胱甘肽(GSH)结合代谢,GST基因多态性显著影响白消安的体内代谢过程。因此可根据患者的基因型,调整白消安用量,制定个体化用药方案。 Busulfan is a commonly used drug in high-dose pretreatment programs before hematopoietic stem cell transplantation (HSCT), with large pharmacokinetic differences and high incidence of adverse reactions among patients. Busulfan is mainly catalyzed by glutathione transferase (GST), which binds to glutathione (GSH) in the liver, and GST gene polymorphisms significantly affect the body’s metabolism in the body. Therefore, according to the patient’s genotype, adjust the amount of busulfan, to develop individualized drug program.